基因治疗对血友病患者健康相关生活质量(HRQoL)域的潜在影响

M. Bullinger, Diandra Latibeaudiere Gardner, H. Lewis, W. Miesbach, Sandra Nolte, J. O’Hara, B. O’Mahony, D. Pollard, M. Skinner, J. Quinn
{"title":"基因治疗对血友病患者健康相关生活质量(HRQoL)域的潜在影响","authors":"M. Bullinger, Diandra Latibeaudiere Gardner, H. Lewis, W. Miesbach, Sandra Nolte, J. O’Hara, B. O’Mahony, D. Pollard, M. Skinner, J. Quinn","doi":"10.17225/jhp00176","DOIUrl":null,"url":null,"abstract":"Abstract Introduction Haemophilia is an inherited bleeding disorder characterised by spontaneous bleeding, often leading to impaired health-related quality of life (HRQoL). Commonly used treatments include episodic and prophylactic treatment regimens. Gene therapies could soon become available, potentially creating a paradigm shift in patient management. Aim This paper proposes hypotheses about the potential impact of gene therapy on HRQoL domains in haemophilia, and how these impacts might differ compared with existing treatments. Methods An expert working group with 10 individuals experienced in haemophilia and HRQoL research was established to discuss potential impacts of gene therapy on HRQoL in general and for specific domains in haemophilia. As part of a one-day workshop, domains of three widely used patient-reported outcome (PRO) instruments were explored: the Haemo-QoL-A, the Patient Reported Outcomes, Burden and Experiences (PROBE), and the Haemophilia Activities List (HAL). Results The group expected a greater improvement in HRQoL from gene therapy compared with existing treatments for the following domains: physical/role functioning, worry, and consequences of bleeding (Haemo-QoL-A); haemophilia-related health and EQ-5D-5L (part of the PROBE); leg and arm function, and leisure activities (HAL). In contrast, the experts suggested that no change or potential deterioration might be observed for the emotional impact (HAL) and treatment concerns (Haemo-QoL-A) domains. Conclusions Current PRO instruments in haemophilia have limitations when applied in the context of gene therapy, and no single instrument fully captures the relevant HRQoL domains. However, the PROBE and Haemo-QoL-A were considered as the most suitable existing instruments. As haemophilia treatments evolve, further research should examine the potential effectiveness of existing PRO instruments as compared to the development of novel PRO measures.","PeriodicalId":372940,"journal":{"name":"The Journal of Haemophilia Practice","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"The potential impact of gene therapy on health-related quality of life (HRQoL) domains in haemophilia\",\"authors\":\"M. Bullinger, Diandra Latibeaudiere Gardner, H. Lewis, W. Miesbach, Sandra Nolte, J. O’Hara, B. O’Mahony, D. Pollard, M. Skinner, J. Quinn\",\"doi\":\"10.17225/jhp00176\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Introduction Haemophilia is an inherited bleeding disorder characterised by spontaneous bleeding, often leading to impaired health-related quality of life (HRQoL). Commonly used treatments include episodic and prophylactic treatment regimens. Gene therapies could soon become available, potentially creating a paradigm shift in patient management. Aim This paper proposes hypotheses about the potential impact of gene therapy on HRQoL domains in haemophilia, and how these impacts might differ compared with existing treatments. Methods An expert working group with 10 individuals experienced in haemophilia and HRQoL research was established to discuss potential impacts of gene therapy on HRQoL in general and for specific domains in haemophilia. As part of a one-day workshop, domains of three widely used patient-reported outcome (PRO) instruments were explored: the Haemo-QoL-A, the Patient Reported Outcomes, Burden and Experiences (PROBE), and the Haemophilia Activities List (HAL). Results The group expected a greater improvement in HRQoL from gene therapy compared with existing treatments for the following domains: physical/role functioning, worry, and consequences of bleeding (Haemo-QoL-A); haemophilia-related health and EQ-5D-5L (part of the PROBE); leg and arm function, and leisure activities (HAL). In contrast, the experts suggested that no change or potential deterioration might be observed for the emotional impact (HAL) and treatment concerns (Haemo-QoL-A) domains. Conclusions Current PRO instruments in haemophilia have limitations when applied in the context of gene therapy, and no single instrument fully captures the relevant HRQoL domains. However, the PROBE and Haemo-QoL-A were considered as the most suitable existing instruments. As haemophilia treatments evolve, further research should examine the potential effectiveness of existing PRO instruments as compared to the development of novel PRO measures.\",\"PeriodicalId\":372940,\"journal\":{\"name\":\"The Journal of Haemophilia Practice\",\"volume\":\"6 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Haemophilia Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17225/jhp00176\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Haemophilia Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17225/jhp00176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

摘要

血友病是一种以自发性出血为特征的遗传性出血性疾病,常导致健康相关生活质量(HRQoL)受损。常用的治疗方法包括间歇性和预防性治疗方案。基因疗法可能很快就会出现,可能会在患者管理方面带来范式转变。目的本文提出了基因治疗对血友病患者HRQoL结构域的潜在影响的假设,以及这些影响与现有治疗方法的差异。方法成立由10名血友病和HRQoL研究专家组成的专家工作组,探讨基因治疗对血友病HRQoL的一般影响和特定领域的潜在影响。作为为期一天的研讨会的一部分,探讨了三种广泛使用的患者报告结果(PRO)仪器的领域:Haemo-QoL-A、患者报告结果、负担和经历(PROBE)和血友病活动清单(HAL)。结果:与现有的治疗方法相比,基因治疗对HRQoL有更大的改善:身体/角色功能、焦虑和出血后果(Haemo-QoL-A);血友病相关健康和EQ-5D-5L(探针的一部分);腿部和手臂功能,以及休闲活动(HAL)。相比之下,专家建议在情绪影响(HAL)和治疗问题(Haemo-QoL-A)领域没有观察到变化或潜在的恶化。结论目前血友病PRO检测仪器在基因治疗中存在局限性,没有一种仪器能完全捕获相关HRQoL结构域。然而,PROBE和Haemo-QoL-A被认为是最合适的现有仪器。随着血友病治疗的发展,进一步的研究应该检查现有PRO仪器的潜在有效性,并与开发新的PRO措施进行比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The potential impact of gene therapy on health-related quality of life (HRQoL) domains in haemophilia
Abstract Introduction Haemophilia is an inherited bleeding disorder characterised by spontaneous bleeding, often leading to impaired health-related quality of life (HRQoL). Commonly used treatments include episodic and prophylactic treatment regimens. Gene therapies could soon become available, potentially creating a paradigm shift in patient management. Aim This paper proposes hypotheses about the potential impact of gene therapy on HRQoL domains in haemophilia, and how these impacts might differ compared with existing treatments. Methods An expert working group with 10 individuals experienced in haemophilia and HRQoL research was established to discuss potential impacts of gene therapy on HRQoL in general and for specific domains in haemophilia. As part of a one-day workshop, domains of three widely used patient-reported outcome (PRO) instruments were explored: the Haemo-QoL-A, the Patient Reported Outcomes, Burden and Experiences (PROBE), and the Haemophilia Activities List (HAL). Results The group expected a greater improvement in HRQoL from gene therapy compared with existing treatments for the following domains: physical/role functioning, worry, and consequences of bleeding (Haemo-QoL-A); haemophilia-related health and EQ-5D-5L (part of the PROBE); leg and arm function, and leisure activities (HAL). In contrast, the experts suggested that no change or potential deterioration might be observed for the emotional impact (HAL) and treatment concerns (Haemo-QoL-A) domains. Conclusions Current PRO instruments in haemophilia have limitations when applied in the context of gene therapy, and no single instrument fully captures the relevant HRQoL domains. However, the PROBE and Haemo-QoL-A were considered as the most suitable existing instruments. As haemophilia treatments evolve, further research should examine the potential effectiveness of existing PRO instruments as compared to the development of novel PRO measures.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Living, Caring, Learning – The treatment centre as family for a woman with severe haemophilia Living, Caring, Learning – Reflections on the therapeutic relationship in haemophilia care Future Care Pathways – A report from the 1st workshop of the EHC Think Tank Workstream on Future Care Pathways The impact of the Contaminated Blood Scandal on the next generation: the state of the evidence Editorial – Living, Caring, Learning: How patients shape the specialist haemophilia nurse
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1